Mania: Gender, transmitter function, and response to treatment

Alan C. Swann; Frederick Petty; Charles L. Bowden; Steven C. Dilsaver; Joseph R. Calabrese; David D. Morris

doi:10.1016/S0165-1781(99)00069-4

Mania: Gender, transmitter function, and response to treatment

Alan C. Swann, Frederick Petty, Charles L. Bowden, Steven C. Dilsaver, Joseph R. Calabrese, David D. Morris

Psychiatry

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Noradrenergic and GABA systems may be involved in mania, but there is little information about relationships between the function of these systems and response to specific antimanic treatments. We investigated relationships between indices of catecholamine or GABA system function, pretreatment mania severity and antimanic response to divalproex, lithium, or placebo. Plasma GABA and urinary excretion of catecholamine metabolites were measured before randomization to lithium, divalproex or placebo in patients hospitalized for manic episodes. Severity of mania was evaluated using the Manic Syndrome, Behavior and Ideation and Mania Rating Scale scores from the SADS-C. Multiple regression analysis showed that pretreatment plasma GABA was related to severity of manic symptoms. This relationship seemed stronger in women. Multiple regression analysis showed that pretreatment levels of urinary MHPG correlated with improvement in manic syndrome scores. These data suggest that GABA and norepinephrine may be related to different aspects of the manic state and to its pharmacologic sensitivity. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original language	English (US)
Pages (from-to)	55-61
Number of pages	7
Journal	Psychiatry Research
Volume	88
Issue number	1
DOIs	https://doi.org/10.1016/S0165-1781(99)00069-4
State	Published - Oct 18 1999

Keywords

Bipolar disorder
GABA
Lithium
MHPG
Norepinephrine
Placebo
Treatment outcome
Valproate

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/S0165-1781(99)00069-4

Fingerprint Dive into the research topics of 'Mania: Gender, transmitter function, and response to treatment'. Together they form a unique fingerprint.

Cite this

@article{bcb3f7a634c34d4ba8423133e512cc0f,

title = "Mania: Gender, transmitter function, and response to treatment",

abstract = "Noradrenergic and GABA systems may be involved in mania, but there is little information about relationships between the function of these systems and response to specific antimanic treatments. We investigated relationships between indices of catecholamine or GABA system function, pretreatment mania severity and antimanic response to divalproex, lithium, or placebo. Plasma GABA and urinary excretion of catecholamine metabolites were measured before randomization to lithium, divalproex or placebo in patients hospitalized for manic episodes. Severity of mania was evaluated using the Manic Syndrome, Behavior and Ideation and Mania Rating Scale scores from the SADS-C. Multiple regression analysis showed that pretreatment plasma GABA was related to severity of manic symptoms. This relationship seemed stronger in women. Multiple regression analysis showed that pretreatment levels of urinary MHPG correlated with improvement in manic syndrome scores. These data suggest that GABA and norepinephrine may be related to different aspects of the manic state and to its pharmacologic sensitivity. Copyright (C) 1999 Elsevier Science Ireland Ltd.",

keywords = "Bipolar disorder, GABA, Lithium, MHPG, Norepinephrine, Placebo, Treatment outcome, Valproate",

author = "Swann, {Alan C.} and Frederick Petty and Bowden, {Charles L.} and Dilsaver, {Steven C.} and Calabrese, {Joseph R.} and Morris, {David D.}",

note = "Funding Information: We gratefully acknowledge the skilled care provided by our nursing staffs. The clinical trial was supported by a grant from Abbott Laboratories. Participants in the multicenter trial included: A Brugger, M.D. and D. Morris, Ph.D., Abbott Laboratories; A. Swann, M.D. and S. Dilsaver, M.D., Harris County Psychiatric Center and University of Texas Health Science Center at Houston; C. Bowden, M.D. and E. Trevino-Garza, M.D., University of Texas Health Science Center at San Antonio; F. Petty, M.D., Ph.D., University of Texas Southwestern Medical School at Dallas; J. Calabrese, M.D., Case Western Reserve Medical School; J. Davis, M.D. and P. Janicak, M.D., Illinois State Psychiatric Institute; S. Risch, M.D., Medical University of South Carolina; J. Small, M.D., University of Indiana Medical School; and P. Goodnick, M.D., University of Miami Medical School. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.",

year = "1999",

month = oct,

day = "18",

doi = "10.1016/S0165-1781(99)00069-4",

language = "English (US)",

volume = "88",

pages = "55--61",

journal = "Psychiatry Research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Mania

T2 - Gender, transmitter function, and response to treatment

AU - Swann, Alan C.

AU - Petty, Frederick

AU - Bowden, Charles L.

AU - Dilsaver, Steven C.

AU - Calabrese, Joseph R.

AU - Morris, David D.

N1 - Funding Information: We gratefully acknowledge the skilled care provided by our nursing staffs. The clinical trial was supported by a grant from Abbott Laboratories. Participants in the multicenter trial included: A Brugger, M.D. and D. Morris, Ph.D., Abbott Laboratories; A. Swann, M.D. and S. Dilsaver, M.D., Harris County Psychiatric Center and University of Texas Health Science Center at Houston; C. Bowden, M.D. and E. Trevino-Garza, M.D., University of Texas Health Science Center at San Antonio; F. Petty, M.D., Ph.D., University of Texas Southwestern Medical School at Dallas; J. Calabrese, M.D., Case Western Reserve Medical School; J. Davis, M.D. and P. Janicak, M.D., Illinois State Psychiatric Institute; S. Risch, M.D., Medical University of South Carolina; J. Small, M.D., University of Indiana Medical School; and P. Goodnick, M.D., University of Miami Medical School. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.

PY - 1999/10/18

Y1 - 1999/10/18

N2 - Noradrenergic and GABA systems may be involved in mania, but there is little information about relationships between the function of these systems and response to specific antimanic treatments. We investigated relationships between indices of catecholamine or GABA system function, pretreatment mania severity and antimanic response to divalproex, lithium, or placebo. Plasma GABA and urinary excretion of catecholamine metabolites were measured before randomization to lithium, divalproex or placebo in patients hospitalized for manic episodes. Severity of mania was evaluated using the Manic Syndrome, Behavior and Ideation and Mania Rating Scale scores from the SADS-C. Multiple regression analysis showed that pretreatment plasma GABA was related to severity of manic symptoms. This relationship seemed stronger in women. Multiple regression analysis showed that pretreatment levels of urinary MHPG correlated with improvement in manic syndrome scores. These data suggest that GABA and norepinephrine may be related to different aspects of the manic state and to its pharmacologic sensitivity. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - Noradrenergic and GABA systems may be involved in mania, but there is little information about relationships between the function of these systems and response to specific antimanic treatments. We investigated relationships between indices of catecholamine or GABA system function, pretreatment mania severity and antimanic response to divalproex, lithium, or placebo. Plasma GABA and urinary excretion of catecholamine metabolites were measured before randomization to lithium, divalproex or placebo in patients hospitalized for manic episodes. Severity of mania was evaluated using the Manic Syndrome, Behavior and Ideation and Mania Rating Scale scores from the SADS-C. Multiple regression analysis showed that pretreatment plasma GABA was related to severity of manic symptoms. This relationship seemed stronger in women. Multiple regression analysis showed that pretreatment levels of urinary MHPG correlated with improvement in manic syndrome scores. These data suggest that GABA and norepinephrine may be related to different aspects of the manic state and to its pharmacologic sensitivity. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - Bipolar disorder

KW - GABA

KW - Lithium

KW - MHPG

KW - Norepinephrine

KW - Placebo

KW - Treatment outcome

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=0032699090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032699090&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(99)00069-4

DO - 10.1016/S0165-1781(99)00069-4

M3 - Article

C2 - 10641586

AN - SCOPUS:0032699090

VL - 88

SP - 55

EP - 61

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -

Mania: Gender, transmitter function, and response to treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this